The ACA's Patient-Centered Outcomes Research Institute will meet Friday to gather public input on whether comparative effectiveness research could inform hepatitis C treatment. Some of the research questions that PCORI will likely be asked to fund target reimbursement restrictions that states have put in place on Gilead Science's hepatitis C drugs, and a PCORI official says the institute does not intend to compare breakthrough hepatitis C drugs to older, less effective treatments. Stakeholders have been urging the institute to fund...